OBJECTIVES: This study is conducted to investigate an effect of simvastatin on cigarette smoke-induced COPD. METHODS: Rats were exposed to air (control) and cigarette smoke (smoking) in presence and absence of simvastatin. Heart and lung tissues were harvested for histopathologic and morphometric analysis. Body weight of rat, mean liner intercept (MLI), mean alveolar number (MAN), lung function test, mean pulmonary artery pressure (mPAP), right ventricular hypertrophy index (RVHI) and 5-HTT level in serum and BALF were examined in experimental rats, respectively. RESULTS: Application of simvastatin mitigated peribronchiolar inflammation and pulmonary bullae formed in the smoke-exposed lungs with weight gain as compared to the smoking rats (P < 0.05). Simvastatin-treated rats showed slight but significant decreases in MLI and MAN with a partial reversal of lung function decline (all P < 0.05). Treatment with simvastatin resulted in a significant decrease not only in mPAP and RVHI but also in a 5-HTT level in serum and BALF (P < 0.01 or 0.05) with a good correlation between the 5-HTT level and mPAP or RVHI (r = 0.693 and 0.479; 0.675 and 0.508). CONCLUSION: Simvastatin partly reverses lung function decline and attenuates structural impairments of lung and right ventricle possibly through reducing 5-HTT content in the model of COPD.
OBJECTIVES: This study is conducted to investigate an effect of simvastatin on cigarette smoke-induced COPD. METHODS:Rats were exposed to air (control) and cigarette smoke (smoking) in presence and absence of simvastatin. Heart and lung tissues were harvested for histopathologic and morphometric analysis. Body weight of rat, mean liner intercept (MLI), mean alveolar number (MAN), lung function test, mean pulmonary artery pressure (mPAP), right ventricular hypertrophy index (RVHI) and 5-HTT level in serum and BALF were examined in experimental rats, respectively. RESULTS: Application of simvastatin mitigated peribronchiolar inflammation and pulmonary bullae formed in the smoke-exposed lungs with weight gain as compared to the smoking rats (P < 0.05). Simvastatin-treated rats showed slight but significant decreases in MLI and MAN with a partial reversal of lung function decline (all P < 0.05). Treatment with simvastatin resulted in a significant decrease not only in mPAP and RVHI but also in a 5-HTT level in serum and BALF (P < 0.01 or 0.05) with a good correlation between the 5-HTT level and mPAP or RVHI (r = 0.693 and 0.479; 0.675 and 0.508). CONCLUSION:Simvastatin partly reverses lung function decline and attenuates structural impairments of lung and right ventricle possibly through reducing 5-HTT content in the model of COPD.
Authors: Matthias Ochs; Jens R Nyengaard; Anja Jung; Lars Knudsen; Marion Voigt; Thorsten Wahlers; Joachim Richter; Hans Jørgen G Gundersen Journal: Am J Respir Crit Care Med Date: 2003-09-25 Impact factor: 21.405
Authors: Toshihiko Nishimura; John L Faul; Gerald J Berry; Laszlo T Vaszar; Daoming Qiu; Ronald G Pearl; Peter N Kao Journal: Am J Respir Crit Care Med Date: 2002-08-15 Impact factor: 21.405
Authors: S Eddahibi; M Humbert; E Fadel; B Raffestin; M Darmon; F Capron; G Simonneau; P Dartevelle; M Hamon; S Adnot Journal: J Clin Invest Date: 2001-10 Impact factor: 14.808
Authors: Saadia Eddahibi; Ari Chaouat; Nicholas Morrell; Elie Fadel; Claire Fuhrman; Anne-Sophie Bugnet; Philippe Dartevelle; Bruno Housset; Michel Hamon; E Weitzenblum; Serge Adnot Journal: Circulation Date: 2003-10-06 Impact factor: 29.690